Europe, the narcolepsy market, is anticipated to reach US$ 1,532.5 Mn in 2027 from US$ 671.1 Mn in 2018. The market is projected to grow with a CAGR of 9.7% from 2019-2027.
The European narcolepsy market is expected to grow due to key driving factors such as growing research and developments and increasing awareness across the region. The market is divided into countries such as Germany, UK, France, Italy, and Spain. In Europe, narcolepsy with cataplexy is a rare disease with an estimated prevalence of 0.02% in European populations. Narcolepsy shares many features of rare disorders, in particular the lack of awareness of the disease with serious consequences for healthcare supply. Similar to other rare diseases, only a few European countries have registered narcolepsy cases in databases of the International Classification of Diseases or in registries of the European health authorities.
Narcolepsy is a rare disease that shows different symptoms in children and adults. The symptoms shown by children are not noticed that much until they reach adulthood. However, the incidences of narcolepsy in children are less and are not estimated due to the undiagnosed of the conditions. According to a study ‘Clinical Characteristics and Burden of Illness in Pediatric Patients with Narcolepsy’ published in 2018 stated that the prevalence of narcolepsy among children between the age of 5 years and below is 13 per 100,000. Whereas, it 83 for every 100,000 children between the age group of 5 years and 19 years. Therefore, it is necessary to raise awareness among the people so as to reduce the symptoms of narcolepsy.
Across, Europe the awareness is increasing significantly, For instance, in Ireland, 22nd September is celebrated as narcolepsy day. Across Ireland, a kite-flying event was conducted. The event was successfully held and the aim to spread awareness of narcolepsy was fulfilled. Similarly in Italy in September 2016, the University of Bologna in collaboration with the Italian Narcolepsy Community conducted a narcolepsy awareness program that involved speakers from Italy, France, and the US to talk about the novel findings and propagate general information to the populace regarding narcolepsy and other sleep-related neurological disorders. Thus, it is estimated that the rising awareness program is likely to influence the growth of the market during the forecast period.
The European narcolepsy market is segmented as type, product and distribution channels. Based on type the market is segmented as narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy. Based on the product the market is categorized as central nervous system (CNS) stimulants, sodium oxybate, and antidepressants. And based on the distribution channel the market is classified as hospital pharmacies and retail pharmacies.
In 2018, the narcolepsy with cataplexy segment held the largest market share of the narcolepsy market, by type. This segment is expected to dominate the market in 2027 owing to the rising episodes of cataplexy that are expected to be encountered among 55-60% of patients suffering from narcolepsy. The segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027.
Some of the significant primary and secondary sources for narcolepsy included in the report are the European Commission, European Medicines Agency, European Union, Associazione Italiana di Medicina del Sonno and others.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the European narcolepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the European narcolepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Teva Pharmaceutical Industries Ltd.
- Jazz Pharmaceuticals plc
- Arena Pharmaceuticals, Inc.
- Graymark Healthcare, Inc.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Mylan N.V.
- BIOPROJET
- Shionogi & Co., Ltd.
- Ligand Pharmaceuticals, Inc